BioNTech Results Presentation Deck

Second Quarter 2020 Financial Results (unaudited) - Balance Sheet 26 Balance Sheet Position 2020 Full Year Financial Guidance Cash and cash equivalents of €573.0m ($641.6m¹) as of June 30, 2020 • After the end of the second quarter, the Company raised €680.7m ($762.2m1) in expected gross proceeds from private equity placement and follow-on underwritten. offering leading to an expected pro-forma cash and cash equivalents balance of €1.25b ($1.40b¹) as of June 30, 2020 Announced debt financing of up to €100.0m ($112.0m¹) from the EIB in June 2020² ● ● ● ● As a result of increased spending related to BNT162, net cash used in operating activities and for purchases of property and equipment expected to be between €450m and €600m for the full year 2020 Existing cash and cash equivalents, the net proceeds from the recent underwritten offering and the expected net proceeds from the private investment are expected to enable the Company to fund operating expenses and capital requirements through at least the next 24 months 1 Translated using the exchange rate published by the German Central Bank (Deutsche Bundesbank) in effect as of June 30, 2020 BIONTECH

View entire presentation